ArticleFrontiers in genetics2025
Copy number variants in fetuses with isolated and non-isolated increased nuchal translucency detected by chromosomal microarray analysis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Copy number variants in fetuses with non-structural ultrasound abnormalities among pregnant women without adverse pregnancy history.Frontiers in genetics · 2026Article
- The Application Value of Chromosome Microarray Analysis in Prenatal Diagnosis of Clinically Relevant Copy Number Variations in Fetuses.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to explore the detection rate of chromosomal copy number variants (CNVs) in fetuses with isolated and non-isolated increased nuchal translucency (NT) by chromosomal microarray analysis (CMA). Methods: A retrospective study was conducted on 211 fetuses with increased NT diagnosed prenatally at Meizhou People's Hospital from November 2022 to June 2025. Interventional prenatal CMA testing was conducted on these fetuses. The detection rates of chromosomal abnormalities in fetuses with isolated and non-isolated increased NT, and fetuses with different NT thicknesses (2.5-3.4, 3.5-4.4, and ≥4.5 mm) were analyzed. Results: Among the fetuses, hromosomal aneuploidy, pathogenic or likely pathogenic (P/LP) CNVs, and variants of uncertain significance (VOUS) were detected in 23, 14, and 26 fetuses respectively, with a total detection rate of 29.9%. A total of 151 fetuses (71.6%) had increased NT, and 60 fetuses (28.4%) had non-isolated increased NT. There was a statistically significant difference in the detection rate of chromosomal abnormalities between the two groups (23.2% vs. 46.7%, χ2=11.311, p=0.001). In fetuses with isolated increased NT, with the increase of NT thickening, the rate of chromosomal aneuploidy shows an increasing trend. And there was statistically significant difference in detection rate of chromosomal aneuploidy in fetuses with different NT thicknesses (p=0.045). Conclusions: A notable difference existed in the detection rate of chromosomal abnormalities between fetuses with isolated and non-isolated increased NT. For those with isolated increased NT, chromosomal aneuploidy rates tended to rise with increasing NT thickness, while this trend was not observed for P/LP CNVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.